潰瘍性結(jié)腸炎是一種慢性非特異性炎癥性疾病，藥物治療主要以達(dá)到臨床緩解、改善患者生存質(zhì)量為主，但這類藥物的長(zhǎng)期使用可能會(huì)引起耐藥性和不良反應(yīng)的問(wèn)題。白藜蘆醇是一種多酚類化合物，可以通過(guò)調(diào)節(jié)免疫細(xì)胞平衡、調(diào)節(jié)炎癥信號(hào)通路、抑制腸道氧化應(yīng)激、調(diào)節(jié)腸道微生物、保護(hù)腸黏膜屏障多種途徑緩解潰瘍性結(jié)腸炎的進(jìn)展，且臨床試驗(yàn)表明補(bǔ)充白藜蘆醇可以緩解潰瘍性結(jié)腸炎患者的癥狀?？偨Y(jié)了白藜蘆醇抗?jié)冃越Y(jié)腸炎的藥理作用和臨床研究的研究進(jìn)展，以期為白藜蘆醇治療潰瘍性結(jié)腸炎提供理論依據(jù)。

Ulcerative colitis is a chronic non-specific inflammatory disease, and drug treatment is mainly aimed at achieving clinical remission and improving patients' quality of life. However, long-term use of drugs may cause drug resistance and adverse reactions. Resveratrol is a polyphenolic compound that can alleviate the progression of ulcerative colitis by regulating immune cell balance, modulating inflammatory signaling pathways, inhibiting intestinal oxidative stress, regulating intestinal microbiota, and protecting the intestinal mucosal barrier. Clinical trials have shown that supplementing with resveratrol can alleviate symptoms in patients with ulcerative colitis. This article summarizes the pharmacological effects and clinical research progress of resveratrol in treatment of ulcerative colitis, in order to provide theoretical basis for the treatment of ulcerative colitis with resveratrol.

R965;R975

國(guó)家自然科學(xué)基金資助項(xiàng)目（81573990）；四川省中醫(yī)藥管理局項(xiàng)目（2020LC0099）；四川省科技廳項(xiàng)目（24RKX0181）